Search Results - "Žitnjak, Daniela"

DEMOGRAPHIC AND CLINICOPATHOLOGIC FEATURES OF PATIENTS WITH PRIMARY BREAST CANCER TREATED BETWEEN 1997 AND 2010: A SINGLE INSTITUTION EXPERIENCE by Žitnjak, Daniela, Soldić, Željko, Kust, Davor, Bolanća, Ante, Kusić, Zvonko

“…Breast cancer accounted for 28% of all new cancers and 18% of female cancer deaths in Europe in 2010. It is the most common type of cancer in women in Croatia,…”
Get full text

Long-Time Survival of a Patient with Metastatic Pancreatic Cancer: A Case Report by Soldic, Zeljko, Zitnjak, Daniela, Bolanca, Ante, Kusic, Zvonko

“…Pancreatic cancer is a malignant neoplasm of the pancreas. It does not cause any symptoms in the early stage, and later symptoms are nonspecific, thus the…”
Get full text

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial by Pfeiffer, Per, Yilmaz, Mette, Möller, Sören, Zitnjak, Daniela, Krogh, Merete, Petersen, Lone Nørgård, Poulsen, Laurids Østergaard, Winther, Stine Braendegaard, Thomsen, Karina Gravgaard, Qvortrup, Camilla

“…TAS-102 (trifluridine–tipiracil) has shown a significant overall survival benefit compared with placebo in patients with chemorefractory metastatic colorectal…”
Get full text

Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC) by Pfeiffer, Per, Yilmaz, Mette, Möller, Sören, Maltha, Line, Krogh, Merete, Zitnjak, Daniela, Szameitat, Caroline Lemb, Hejlesen, Finn, Thomsen, Karina Gravgaard, Qvortrup, Camilla

“…Abstract only 637 Background: Trifluridine/tipiracil (FTD/TPI, also known as TAS-102) is approved for the use in patients with chemorefractory mCRC. Inspired…”
Get full text

Demografska i kliničko-patološka obilježja bolesnica s primarnim rakom dojke liječenih u razdoblju od 1997. do 2010. godine: iskustvo jedne klinike by Žitnjak, Daniela, Soldić, Željko, Kust, Davor, Bolanča, Ante, Kusić, Zvonko

“…U europskoj populaciji rak dojke činio je 2010. godine 28% svih novodijagnosticiranih zloćudnih tumora te bio uzrokom smrti u 18% žena oboljelih od raka. Prvi…”
Get full text

Long-time survival of a patient with metastatic pancreatic cancer: a case report by Soldic, Zeljko, Zitnjak, Daniela, Bolanca, Ante, Kusic, Zvonko

Get full text